These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 15111618)
1. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. Zander AR; Kröger N; Schmoor C; Krüger W; Möbus V; Frickhofen N; Metzner B; Schultze W; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Trümper L; Kreienberg R; Carstensen M; Schmidt EH; Jänicke F; Schumacher M; Jonat W J Clin Oncol; 2004 Jun; 22(12):2273-83. PubMed ID: 15111618 [TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638 [TBL] [Abstract][Full Text] [Related]
3. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418 [TBL] [Abstract][Full Text] [Related]
4. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
5. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605 [TBL] [Abstract][Full Text] [Related]
8. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610 [TBL] [Abstract][Full Text] [Related]
9. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Zander AR; Schmoor C; Kröger N; Krüger W; Möbus V; Frickhofen N; Metzner B; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Kreienberg R; Schumacher M; Jonat W Ann Oncol; 2008 Jun; 19(6):1082-9. PubMed ID: 18304964 [TBL] [Abstract][Full Text] [Related]
10. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study. Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213 [TBL] [Abstract][Full Text] [Related]
11. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment. Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359 [TBL] [Abstract][Full Text] [Related]
12. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. Moebus V; Jackisch C; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Schneeweiss A; Huober J; Harbeck N; von Minckwitz G; Runnebaum IB; Hinke A; Kreienberg R; Konecny GE; Untch M J Clin Oncol; 2010 Jun; 28(17):2874-80. PubMed ID: 20458045 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG; N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087 [TBL] [Abstract][Full Text] [Related]
15. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043 [TBL] [Abstract][Full Text] [Related]
17. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. Gluz O; Mengele K; Schmitt M; Kates R; Diallo-Danebrock R; Neff F; Royer HD; Eckstein N; Mohrmann S; Ting E; Kiechle M; Poremba C; Nitz U; Harbeck N J Clin Oncol; 2009 Dec; 27(36):6144-51. PubMed ID: 19901122 [TBL] [Abstract][Full Text] [Related]
18. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307 [TBL] [Abstract][Full Text] [Related]
19. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Biron P; Durand M; Roché H; Delozier T; Battista C; Fargeot P; Spaeth D; Bachelot T; Poiget E; Monnot F; Tanguy ML; Curé H Bone Marrow Transplant; 2008 Mar; 41(6):555-62. PubMed ID: 18037940 [TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes. Lalisang RI; Hupperets PS; ten Haaft MA; Jansen RL; Schouten HC Bone Marrow Transplant; 1998 Feb; 21(3):243-7. PubMed ID: 9489646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]